
News|Articles|December 19, 2025
Moderate-to-Severe OSA Tied to Doubled Risk of Brain Microbleeds: Daily Dose
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On November 6, 2025, we reported on a study published in JAMA Network Open that was designed to examine the association between obstructive sleep apnea (OSA) severity and risk of incident cerebral microbleeds (CMBs) in middle-aged and older adults.
The study
Researchers drew participants from the Korean Genome and Epidemiology Study (KoGES), an ongoing longitudinal investigation. Between 2011 and 2014, participants underwent baseline in-home polysomnography and brain MRI, with follow-up assessments at 4-year intervals through 2022. The prospective cohort study included 1441 adults.
OSA severity was categorized by apnea-hypopnea index (AHI) as: no OSA (0-4.9 events/hour), mild OSA (5.0-14.9 events/hour), and moderate to severe OSA (15.0 or more events/hour). The study excluded participants with baseline microbleeds, history of cerebrovascular or cardiovascular disease, or missing covariates.
The findings
The cumulative incidence of CMBs was:
At 4 years: 1.85% (no OSA), 1.61% (mild), 4.66% (moderate-to-severe)
At 8 years: 3.33% (no OSA), 3.21% (mild), 7.25% (moderate-to-severe)
In multivariable models that adjusted for demographics, cardiovascular risk factors, white matter changes, and longitudinal changes in AHI and BMI, only the 8-year risk for moderate to severe OSA remained significantly elevated.
Authors' comments
"In this study, moderate to severe OSA was independently associated with an increased risk of incident CMBs over an 8-year follow-up. These results add to the evidence for the importance of sleep apnea to brain health."
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Early Liver Disease Detection Starts in Primary Care: A Q&A With Stevan Gonzalez, MD
2
2026 Dyslipidemia Guideline Expands Statin Eligibility to 21.5 Million More US Adults
3
FDA Fast Tracks Remlifanserin Development for Alzheimer Disease Psychosis
4
Early Lyme Disease Detection Improved With Single-Step Tests in New Study
5





























































































































































